{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:12Z","timestamp":1762323972368},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"New Faculty Startup Fund"},{"DOI":"10.13039\/100008114","name":"University of Nebraska-Lincoln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bioorg.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T14:09:09Z","timestamp":1469542149000},"page":"105-111","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor"],"prefix":"10.1016","volume":"68","author":[{"given":"Tong","family":"Ju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duoyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Hua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiantao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2016.07.012_b0005","unstructured":"UNAIDS, Data and analysis, 2014. <http:\/\/www.unaids.org\/en\/>."},{"key":"10.1016\/j.bioorg.2016.07.012_b0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.chom.2012.09.008","article-title":"A blueprint for HIV vaccine discovery","volume":"12","author":"Burton","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bioorg.2016.07.012_b0015","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1016\/j.vaccine.2011.11.014","article-title":"HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem","volume":"30","author":"Koff","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.bioorg.2016.07.012_b0020","first-page":"S1359","article-title":"An analysis of FDA-approved drugs for infectious disease: HIV\/AIDS drugs","author":"Kinch","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2016.07.012_b0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2013.03.017","article-title":"Entry inhibitors and their use in the treatment of HIV-1 infection","volume":"98","author":"Haqqani","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2016.07.012_b0030","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2016.07.012_b0035","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2016.07.012_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/157016212799937191","article-title":"The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study","volume":"10","author":"Qiu","year":"2012","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.bioorg.2016.07.012_b0050","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2016.07.012_b0055","doi-asserted-by":"crossref","first-page":"13697","DOI":"10.1021\/bi9606962","article-title":"HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41","volume":"35","author":"Lawless","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2016.07.012_b0060","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1128\/JVI.01109-10","article-title":"A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5","volume":"84","author":"Tilton","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0065","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2016.07.012_b0070","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2016.07.012_b0075","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2016.07.012_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2009.07.022","article-title":"Entry inhibitors in the treatment of HIV-1 infection","volume":"85","author":"Tilton","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2016.07.012_b0085","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0272-2712(02)00011-2","article-title":"HIV-1 entry and entry inhibitors as therapeutic agents","volume":"22","author":"Starr-Spires","year":"2002","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.bioorg.2016.07.012_b0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0092-8674(00)80577-2","article-title":"Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry","volume":"96","author":"Farzan","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2016.07.012_b0095","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.1145373","article-title":"Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4","volume":"317","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2016.07.012_b0100","doi-asserted-by":"crossref","first-page":"33516","DOI":"10.1074\/jbc.M007228200","article-title":"A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry","volume":"275","author":"Farzan","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(03)00508-7","article-title":"Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120","volume":"114","author":"Choe","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2016.07.012_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2016.07.012_b0115","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1128\/JVI.79.10.6068-6077.2005","article-title":"Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody","volume":"79","author":"Xiang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.virol.2013.01.002","article-title":"Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2","volume":"438","author":"Xiang","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.bioorg.2016.07.012_b0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1248\/cpb.41.376","article-title":"Evaluation of the final deprotection system for the solid-phase synthesis of Tyr(SO3H)-containing peptides with 9-fluorenylmethyloxycarbonyl (Fmoc)-strategy and its application to the synthesis of cholecystokinin (CCK)-12","volume":"41","author":"Yagami","year":"1993","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2016.07.012_b0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1399-3011.1994.tb00522.x","article-title":"Solid-phase synthesis of cionin, a protochordate-derived octapeptide related to the gastrin\/cholecystokinin family of peptides, and its mono-tyrosine-sulfate-containing derivatives","volume":"43","author":"Kitagawa","year":"1994","journal-title":"Int. J. Pept. Protein Res."},{"key":"10.1016\/j.bioorg.2016.07.012_b0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1248\/cpb.49.958","article-title":"Facile solid-phase synthesis of sulfated tyrosine-containing peptides: Part II. Total synthesis of human big gastrin-II and its C-terminal glycine-extended peptide (G34-Gly sulfate) by the solid-phase segment condensation approach","volume":"49","author":"Kitagawa","year":"2001","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2016.07.012_b0140","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0968-0896(00)00041-9","article-title":"Chemoenzymatic synthesis of PSGL-1 glycopeptides: sulfation on tyrosine affects glycosyltransferase-catalyzed synthesis of the O-glycan","volume":"8","author":"Koeller","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jo000895y","article-title":"Facile solid-phase synthesis of sulfated tyrosine-containing peptides: total synthesis of human big gastrin-II and cholecystokinin (CCK)-39","volume":"66","author":"Kitagawa","year":"2001","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/bip.20821","article-title":"Toward a framework for sulfoproteomics: synthesis and characterization of sulfotyrosine-containing peptides","volume":"90","author":"Seibert","year":"2008","journal-title":"Biopolymers"},{"key":"10.1016\/j.bioorg.2016.07.012_b0155","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1016\/S0040-4020(01)81989-X","article-title":"Syntheses of 2 tyrosine sulfate containing peptides, leucosulfakinin (Lsk)-II and cholecystokinin (Cck)-12, using the O-para-(methylsulfonyl)benzyl serine for the selective sulfation of tyrosine","volume":"48","author":"Futaki","year":"1992","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2016.07.012_b0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1039\/c39870000323","article-title":"Total synthesis of porcine cholecystokinin-33 (Cck-33)","author":"Kurano","year":"1987","journal-title":"J. Chem. Soc. Chem. Commun."},{"key":"10.1016\/j.bioorg.2016.07.012_b0165","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/1521-3773(20020916)41:18<3449::AID-ANIE3449>3.0.CO;2-U","article-title":"A strategy for the synthesis of sulfated peptides","volume":"41","author":"Young","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2016.07.012_b0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/ja00704a033","article-title":"Synthesis of cholecystokinin-pancreozymin. I. The C-terminal dodecapeptide","volume":"92","author":"Ondetti","year":"1970","journal-title":"J. Am. Chem. Soc."},{"year":"2002","series-title":"Chlorosulfonic Acid: A Versatile Reagent","author":"Cremlyn","key":"10.1016\/j.bioorg.2016.07.012_b0175"},{"key":"10.1016\/j.bioorg.2016.07.012_b0180","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1039\/c3mb70061e","article-title":"Molecular recognition of sulfotyrosine and phosphotyrosine by the Src homology 2 domain","volume":"9","author":"Ju","year":"2013","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.bioorg.2016.07.012_b0185","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1039\/P19900001739","article-title":"Use of dimethylformamide sulfur-trioxide complex as a sulfating agent of tyrosine","author":"Futaki","year":"1990","journal-title":"J. Chem. Soc. Perk. Trans. 1"},{"key":"10.1016\/j.bioorg.2016.07.012_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jo000895y","article-title":"Facile solid-phase synthesis of sulfated tyrosine-containing peptides: total synthesis of human big gastrin-II and cholecystokinin (CCK)-39(1,2)","volume":"66","author":"Kitagawa","year":"2001","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.provac.2015.05.002","article-title":"Stabilization of outer domain of gp120 from HIV-1 subtype C for vaccine immunogen design","volume":"9","author":"Thompson","year":"2015","journal-title":"Proc. Vaccinol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0200","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0205","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0210","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1021\/cb400691z","article-title":"Tyrosine O-prenyltransferase SirD catalyzes S-, C-, and N-prenylations on tyrosine and tryptophan derivatives","volume":"8","author":"Rudolf","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2016.07.012_b0215","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1021\/jm2001426","article-title":"Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies","volume":"54","author":"Zakharova","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2016.07.012_b0220","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/ol300831t","article-title":"Total synthesis of mycocyclosin","volume":"14","author":"Cochrane","year":"2012","journal-title":"Org. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206816301742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206816301742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T18:37:21Z","timestamp":1568227041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206816301742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":44,"alternative-id":["S0045206816301742"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2016.07.012","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}